ClinicaliQ Trial Snapshot
- Study of TGM-312-SC01 in Healthy Participants and Adults With MASH — Recruiting • Phase I / Phase II • Diabetes / Metabolic • NCT07427680.
- Review the linked registry entry for study design, population, endpoints, and operational status.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) effects of single ascending doses of TGM-312-SC01 in healthy adults and multiple ascending doses in patients with metabolic dysfunction-associated steatohepatitis (MASH). Conditions: Healthy Participants, MASH - Metabolic Dysfunction-Associated Steatohepatitis Interventions: TGM-312-SC01, Placebo Lead Sponsor: Tangram Therapeutics Plc Planned Enrollment: 99 participants